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Objective: Huntington’s disease (HD) gene carriers can be identified before clinical diagnosis; however, statistical
models for predicting when overt motor symptoms will manifest are too imprecise to be useful at the level of the
individual. Perfecting this prediction is integral to the search for disease modifying therapies. This study aimed to
identify an imaging marker capable of reliably predicting real-life clinical diagnosis in HD.
Method: A multivariate machine learning approach was applied to resting-state and structural magnetic resonance
imaging scans from 19 premanifest HD gene carriers (preHD, 8 of whom developed clinical disease in the 5 years
postscanning) and 21 healthy controls. A classification model was developed using cross-group comparisons between
preHD and controls, and within the preHD group in relation to “estimated” and “actual” proximity to disease onset.
Imaging measures were modeled individually, and combined, and permutation modeling robustly tested classification
accuracy.
Results: Classification performance for preHDs versus controls was greatest when all measures were combined. The
resulting polymarker predicted converters with high accuracy, including those who were not expected to manifest in
that time scale based on the currently adopted statistical models.
Interpretation: We propose that a holistic multivariate machine learning treatment of brain abnormalities in the pre-
manifest phase can be used to accurately identify those patients within 5 years of developing motor features of HD,
with implications for prognostication and preclinical trials.
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Huntington’s disease (HD) is an autosomal-dominant,fatal, neurodegenerative condition which is caused
by an abnormal CAG expansion located within exon 1
of the huntingtin gene.1 Because of its monogenic cause,
HD gene carriers can be identified before the appearance
of overt clinical signs, providing a privileged window
through which to observe the preclinical pathogenic
pathways in HD. It also creates an opportunity to inter-
vene before the onset of clinical disease using neuropro-
tective therapies or disease-modifying drugs.
However, establishing the efficacy of any such treat-
ment in a premanifest population presents several
practical challenges. The prevalence of HD is just 12 per
100,0002 and with less than 1 in 5 “at-risk” individuals
undergoing predictive testing,3 the number of known
premanifest HD gene carriers is small. Furthermore, HD
is a slow progressing disease with a large variance in age
of onset, especially for individuals with smaller CAG
repeat lengths.4,5 Currently, proximity to clinical diagno-
sis is estimated using statistical models based upon CAG
repeat length and age.4,6 However, the CAG repeat
length only accounts for between 50% and 69% of the
variance observed in age at diagnosis.6–8 Consequently,
the statistical estimations of proximity to diagnosis are
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unreliable at the level of the individual,5 resulting in the
need for increased sample sizes to adequately power pre-
manifest clinical trials.
Researchers have postulated that neuroimaging
markers of structural, functional, and connectivity
changes in the premanifest brain have a more predictable
relationship with the onset of clinically diagnosable
HD.9–11 Over the past 5 years, the number of different
imaging techniques has rapidly increased. Although each
technique has its own individual merit, it is difficult to
establish which one (or more than one) is the most suit-
able for use as a premanifest biomarker. Furthermore, the
efficacy of the imaging biomarkers is judged by the
strength of its relationship with the statistical estimates of
proximity to diagnosis creating a circular problem.
In this study, we sought to address these issues by
comparing three distinct neuroimaging measures—
resting-state functional connectivity, subcortical gray mat-
ter volume, and cortical thickness—in a population of
premanifest HD gene carriers (preHD) and age-matched
controls before evaluating the utility of a novel bio-
marker, which combined all three. Importantly, while all
participants were classified as preHD at the time of scan-
ning, 42% received a diagnosis of clinical disease within
5 years; for these participants, real-life time to diagnosis
was also used. A multivariate machine learning approach
was applied in combination with robust permutation
modeling to determine the potential of each measure, for
correctly classifying preHD from controls and for identi-
fying which preHD would receive a clinical diagnosis
within 5 years. Our prediction was that a holistic treat-
ment of the data, that took into account all markers
combined, would produce the most accurate clinical
marker.12 Finally, to validate this approach we conducted
an independent validation with independent structural
data (functional data were not available) from the
TRACK-HD13 consortium.
Patients and Methods
Cambridge Cohort
Nineteen preHD individuals (confirmed CAG expansion) and
21 age-matched controls were recruited from the HD clinic at
the John Van Geest Centre for Brain Repair (Cambridge, UK).
Ethical Approval was granted by the Local Research Ethics
Committee’s and informed consent was taken from participants.
The preHD group was median-split into preHD-near and
preHD-far subgroups according to their estimated years to clin-
ical diagnosis score calculated using the Langbehn model4
TABLE 1. Demographics of the Cambridge Cohort and TRACK-HD Partial Independent Validation Cohort at
Baseline
Premanifest Baseline
Classificationd
Premanifest Follow-up
Classificatione
Pre-HD Controls Far Near Converter Nonconverter
Cambridge cohort
Number 19 21 9 10 8 (3a) 11
Age,y 45.5 (11.5) 41.9 (12.2) 41.9 (11.7) 48.7 (11.5) 50.5 (9.3) 41.9 (11.9)
Estimated years to diagnosisc 16.1 (8.4) — 22.8 (7.4) 10.1 (2.7) 12.7 (7.6) 18.6 (8.4)
Disease burden scoreb 241.8 (77.2) — 181.5 (38.1) 296.1 (60.9) 276.0 (91.8) 217.0 (56.6)
TRACK-HD cohort
No. 118 121 60 58 42 (20a) 76
Age, y 40.8 (8.9) 46.3 (10.1) 42. (11.1) 48.7 (11.5) 50.5 (9.4) 42.8 (11.8)
Estimated years to diagnosisc 8.1 (4.9) — 11.5 (3.8) 4.5 (2.8) 6.0 (3.7) 7.9 (5.1)
Disease burden scoreb 274.7 (49.2) — 237.9 (31.4) 312.8 (32.5) 295.1 (46.2) 278.6 (50.1)
aPredicted to convert within follow-up period based upon the Langbehnf equation.
bDisease burden score5 age3 (CAG-35.5).
cCalculated using the Langbehn equation.f
dDivided by the whole Pre-HD group median (13.6 for the Cambridge cohort; 10.8 years for the TRACK-HD cohort).
eDivision based upon the presence of a clinical diagnosis of HD at the time of follow-up.
fTaken from Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR; International Huntington’s Disease Collaborative Group. A new
model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet 2004;65:267–277.
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(median5 13.6 years). The cohort was then tracked for 5 years,
during which time 8 preHD developed overt motor symptoms
(HD-converters; see Table 1 for demographics).
Data Acquisition
Resting-state functional magnetic resonance imaging (fMRI;
300 T2*-weighted volumes: repetition time5 2 seconds, echo
time5 30ms, 3mm3 voxels) and structural (1mm3
magnetization-prepared rapid gradient echo) scans were con-
ducted using a 3 Tesla Siemens TIM Trio MRI at the MRC
Cognition and Brain Sciences Unit (Cambridge, UK).
Independent Cohort Validation
Classification models were validated with independent data
from the TRACK-HD consortium. One hundred eighteen
preHD and 121 controls were recruited internationally from
four sites (see earlier works13,14 for details; Table 1). The
preHD group were divided into “near” and “far” subgroups
using the same methodology described above (median5 10.8
years). These independent data provided an opportunity to test
the generalizability of the structural models’ generalizability
(fMRI data were not available).
fMRI Processing
fMRI data were preprocessed using SPM8 (www.fil.ion.ucl.ac.uk/
spm). Images were slice-timing and motion corrected, coregis-
tered to the structural image, normalized to 2mm3 Montreal
Neurological Institute (MNI) space and spatially smoothed
(8mm). Maps of canonical resting-state networks (RSNs) were
taken from a previous study15 and used to compare network cou-
plings between groups. Time courses extracted16 for each RSN
were used to calculate beta estimates for each RSN pair using two
general linear models with the time course of one RSN as a
dependent variable in one model and as an independent variable
in the second. Individuals motion parameters and white-matter
time courses were modeled as nuisance regressors (N.B.). Motion
did not differ across groups (framewise displacement [t5 –
0.0016; p5 0.9863); root mean square error [t5 –0.0015;
p5 0.3964]; spikes (t5 1.331; p5 0.1911]). Averaging across
the two betas from each RSN pair produced 171 estimates of
connectivity, or “coupling strengths” per individual.
Structural Features
Estimates of cortical thickness (CT) and subcortical volumes
(SCVs) were calculated using FreeSurfer (https://surfer.nmr.
mgh.harvard.edu) and the Destrieux atlas.17
Machine Learning
A linear support vector machine (SVM) was implemented in
MATLAB (R2015b; The MathWorks, Inc., Natick, MA) and
was trained to classify the preHD and control groups. For each
model, the input data were standardized, age and imaging site
regressed out, and normalized using a rank-based inverse trans-
form. Models were trained using a linear kernel, sequential
minimal optimization (SMO) and a weighted cost function to
account for class imbalances. Models were robustly evaluated
using leave-one-out validation and permutation testing (1,000
iterations) of the models F1 scores, which, as the harmonic
mean of the models sensitivity and precision, represents a more
informative metric than classification accuracy when classes are
imbalanced. Similar to classification accuracy, F1-score chance
is determined by the null distribution (50% in binary cases).
Empirical probability values were calculated for each true model
by its ranked F1 score relative to its permuted null distribution,
for example, F1-scores> 99% of the permuted models equal a
p value< 0.01.
An independent validation was applied across the Cam-
bridge and TRACK-HD cohorts. Models were trained with
SCVs to differentiate specific subgroups within the TRACK-
HD data set and then assessed by its F1 score when tested on
the same subgroups within the Cambridge cohort against a per-
muted distribution (1,000 iterations).
In summary, RSN connectivity, CT, and SCVs were com-
pared across preHD and controls and evaluated as correlates of
clinical diagnosis. These measures were then evaluated as pre-
dictors of clinical diagnosis with binary SVMs. Finally, SVMs
were trained with SCVs and tested on an independent sample
(see Fig 1 for a schematic of the analysis).
Results
Resting-State Network Coupling
CROSS-GROUP ANALYSIS. RSNs coupling were entered
into a repeated-measures analysis of variance (ANOVA) with
Connection as the within-participant factor (171 levels) and
FIGURE 1: High-level schematic of the analysis approach. In
the Cambridge cohort, both resting-state fMRI and struc-
tural images were available, only structural images were
available for the TRACK-HD cohort. Colors represent the
independent samples used for different aspects of the anal-
ysis (blue5Cambridge cohort [19 preHD, 21 controls];
green5TRACK-HD cohort [118 preHD, 121 controls]).
fMRI5 functional magnetic resonance imaging; SVM5 sup-
port vector machine.
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Group (preHD vs controls) as the between participant
factor. There was a main effect of Connection (F(170,6460)
5 42.264; p< 0.001; gG25 0.490) and a significant Group
* Connection interaction (F(170,6460)5 1.986; p< 0.001;
gG25 0.043), indicating that some RSN coupling strengths
differed across groups. The was no main effect of Group.
To characterize the basis of these effects, we com-
pared RSN couplings across groups using two-sample t
tests with an uncorrected two-tailed threshold of p< 0.02,
which identified 10 RSN connections with lower coupling
strengths in preHD. Notably, a network that included the
anterior insula/inferior frontal operculum (AIFO) and
regions of the striatum featured in five of these reduced
couplings (Fig 2A). Five couplings showed heightened net-
work coupling at the same threshold. This approach was
advantageous because it identified couplings that be aver-
aged across to form two composite scores (hypoconnectiv-
ity and hyperconnectivity).
FIGURE 2: (A) Schema ball depicting cross-group differences in resting state network coupling (connections thresholded at
p<0.02 uncorrected). Blue curves represent reduced network coupling and the red curves represent increased network cou-
pling for the preHD group relative to controls. (B) Table showing correlations for the hypoconnected network measures and
estimated years to diagnosis. (C) Scatterplot of the correlation between the mean values for composite hypoconnected net-
work measures and estimated years to diagnosis.
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ANALYSIS OF DISEASE COURSE. Hypoconnectivity
and hyperconnectivity were correlated against estimated
years to clinical diagnosis (Fig 2c; N.B; this measure was
not normally distributed [ks5 1; p< 0.001]; therefore,
Spearman correlations were calculated here, and through-
out). The hypoconnectivity measure showed a strong
positive correlation with estimated years to clinical diag-
nosis4 (r5 0.581; p5 0.009, 95% confidence interval
[CI; 0.391 0.723]) and a strong negative correlation with
the CAG-Age Product Scaled (CAPs) 18 score (r5 –
0.526; p5 0.01; 95% CI [–0.682 –0.322]). A Steiger z-
test demonstrated that estimated years to clinical diagno-
sis explained a significantly larger amount of variance in
hypoconnectivity scores than did the CAPs measure
(z5 2.568; p5 0.01) and was therefore not used going
forward. An exploratory analysis revealed that the major-
ity of the significant hypoconnectivity connections,
including all of those with the AIFO network, showed
significant positive correlations with estimated years to
clinical diagnosis (Fig 2b).
Hypoconnectivity did not correlate with CAG
repeat number (r5 –0.241; p5 0.8401, 95% CI [–0.459
0.004]) or Age (r5 –0.385; p5 0.1033; 95% CI [–
0.155 –0.575]) and the relationship to estimated years to
clinical diagnosis remained when age was factored out in
a partial correlation (r5 0.433; p5 0.036, one-tailed,
95% CI [0.210 0.612]). Finally, hyperconnectivity scores
did not correlate with estimated years to clinical diagno-
sis (r5 –0.2877; p5 0.2322, 95% CI [–0.497, –0.046]).
The ANOVA was repeated using the preHD sub-
groups to model the proximity to disease onset. There
was a main effect of Connection (F(170,6290)5 37.884;
p< 0.001; gG25 0.472) and a significant Group * Con-
nection interaction (F(340,6290)5 1.669; p< 0.001;
gG25 0.073). There was no main effect of Group.
Because of connectivity effects going in opposing direc-
tions (as observed in the higher-level analysis), a Tukey
post-hoc analysis revealed no group effects. However, a
comparison of the hypoconnectivity composite between
groups using a one-way ANOVA revealed a main effect
of Group (F(2,37)5 15.476; p< 0.001). The Tukey post-
hoc analysis showed that the preHD-near group had
lower hypoconnectivity scores than the preHD-far
(p5 0.016; 95% CI [–0.336, –0.030]) and control
(p< 0.001; 95% CI [–0.419, –0.163]) groups. Critically,
the preHD-far group did not differ from the control
group (p5 0.131; 95% CI [–0.025, 0.240]). Taken
together, the connectivity data demonstrate that the pre-
manifest HD show reduced RSN coupling, primarily in
networks paired with the AIFO, and these abnormalities
increase as they reached clinical diagnosis.
Subcortical Volumetrics
CROSS-GROUP ANALYSIS. SCVs were entered into a
repeated-measures ANOVA with Structure (six levels) as the
within-participant factor, Group (preHD, control) as the
between-participant factor, and Age modeled as a covariate.
There was a main effect of Structure (F(5,185)5 105.645;
p< 0.001; gG25 0.596) and significant Structure * Group
(F(5,185)5 4.800; p< 0.001; gG
25 0.063) and Structure *
Age (F(5,185)5 2.740; p5 0.021; gG
25 0.037) interactions
(Fig 3). There was no main effect of Group.
To characterize the basis of the interaction, each
SCV was modeled in a one-way ANOVA with Group
(preHD-near, preHD-far, and controls) as the between-
participant factor. There were significant Group effects
on caudate (F(2,37)5 5.520; p5 0.008; g
25 0.229),
putamen (F(2,37)5 4.792; p5 0.014; g
25 0.205), and
pallidum (F(2,37)5 4.502; p5 0.018; g
25 0.195)
FIGURE 3: (A) Subcortical gray matter volume of the preHD-near (light gray), preHD-far (gray) and the matched control (light
gray) groups. Each bar is accompanied by an image with the associated structure highlighted in black. Error bars report the
standard error of the mean (**p<0.01; *p<0.05). (B) Scatterplot showing the correlation between Putamen (black dots), Cau-
date (gray dots), and Pallidum (light-gray dots) volume (collapsed across hemisphere) with Estimated years to disease onset.
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volumes. Post-hoc Tukey analyses demonstrated that the
preHD-near group had significantly lower caudate
(p5 0.006, 95% CI [–1,223.738, –186.021]), putamen
(p5 0.011, 95% CI [–1,836.311, –207.492]), and
pallidum (p5 0.018, 95% CI [–477.248, –38.329])
volumes than the controls whereas the preHD-far
and preHD-near groups (Caudate: p5 0.117; 95% CI
[–1,139.057 101.918]; Putamen: p5 0.368; 95%
CI [–1,519.562, 428.295]; Pallidum: p5 0.061; 95% CI
[–515.248, 9.641]) and the preHD-far and control
groups (Caudate: p5 0.678; 95% CI [–724.341,
351.720]; Putamen: p5 0.363, 95% CI [–1,320.771,
368.235]; Pallidum: p5 0.998; 95% CI [–232.554,
222.582]) did not differ.
ANALYSIS OF DISEASE COURSE. Estimated years to
disease onset significantly correlated with caudate
(r5 0.496; p5 0.031; 95% CI [0.285, 0.660]) and pal-
lidum (r5 0.596; p5 0.007; 95% CI [0.411, 0.733])
volumes, whereas putamen volume did not correlate
(r5 0.372; p5 0.117; 95% CI [0.139, 0.565]; Fig 3b).
The correlation between caudate volume and estimated
years to clinical diagnosis remained when age was fac-
tored out using a partial correlation (r5 0.471;
p5 0.049; 95% CI [0.255, 0.641]). Therefore, the
preHD group had reduced volumes in specific subcorti-
cal structures relative to controls, and these abnormalities
became more pronounced as they approached clinical
diagnosis.
Cortical Thickness
CROSS-GROUP ANALYSIS. CT measures were entered
into a repeated-measures ANOVA with Parcel (74 levels)
and Hemisphere (Left vs Right) as the within-participant
factors, Group (preHD, control) as the between-participant
factor and Age modeled as a covariate (N.B. We observed
no evidence of quadratic effects). There were main effects of
Group (F(1,37)5 5.410; p5 0.026; gG
25 0.024) and Par-
cel (F(73,2701)5 18.970; p< 0.001; gG
25 0.181), and sig-
nificant Group * Parcel (F(73,2701)5 1.473; p5 0.006;
gG25 0.016) and Parcel * Age (F(73,2701)5 2.022;
p< 0.001; gG25 0.023) interactions.
A comparison of Mean CT across Groups using a
one-way ANOVA showed a main effect of Group
(F(2,37)5 6.132; p5 0.005; g
250.249). A Tukey post-
hoc analysis demonstrated that mean CT was significantly
lower in the preHD-near compared to the control group
(p5 0.004; 95% CI [–0.211, –0.036]) with a subthresh-
old difference compared to the preHD-far group
(p5 0.062; 95% CI [–0.204, 0.004]). The preHD-far
and controls did not differ (p5 0.797; 95% CI [–0.066
0.114]; Fig 4A).
ANALYSIS OF DISEASE COURSE. Estimated years to
disease onset showed a positive correlation with mean
CT (r5 0.628; p5 0.004; 95% CI [0.452, 0.756]; Fig
4B), which remained when age was factored out using a
partial correlation (r5 0.579; p5 0.012; 95% CI [0.389,
0.721]). Therefore, the preHD group had reduced CT
relative to controls and these abnormalities became more
pronounced as they approached clinical diagnosis.
Cross-Group Classification Using a SVM
Next, determined whether the entire RSN coupling
strengths, CT and SCVs feature sets could be used to clas-
sify the preHD group in a holistic manner using SVMs
and permutation testing (see Materials and Methods).
We first classified the preHD and controls based on
either their RSN coupling strengths, SCVs, or the CTs
independently, or combined as a polymarker (Table 2,
row 1). The SVMs performed significantly higher than
chance for each feature set (Rest: F15 67%; p< 0.02;
FIGURE 4: (A) Comparisons of cortical thickness (collapsed across hemisphere) between the Controls (dark gray), preHD-far
(medium gray), and preHD-near (light gray) groups. Error bars represent the standard error of the mean (***p50.001). (B) A
scatterplot showing the correlation between mean cortical thickness & estimated years to diagnosis.
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CT: F15 65%; p< 0.02; SCVs: F15 72%; p< 0.02;
polymarker: F15 74%; p< 0.01).
We next observed a clear distinction in classifying
the preHD-near and far groups from controls. The
preHD-near group was successfully classified from con-
trols (Table 2, row 3) with the Rest (F15 87%;
p< 0.001), SCV (F15 73%; p< 0.05), and the poly-
marker (F15 84%; p< 0.001) feature sets. Conversely,
the preHD-far group was not classified from the controls
with above chance accuracy (Table 2, row 2).
Finally, we classified the 8 individuals who had
received clinical diagnoses in the time between data
acquisition and the end of the study (Table 2, rows 4
and 5). Converted-HD were classified from controls well
above chance using the SCV (F15 88%; p< 0.01) and
the polymarker (F15 81%; p< 0.001) feature sets.
Predicting Clinical Diagnosis
RELATIONSHIP BETWEEN HD CLINICAL DIAGNOSIS
AND ESTIMATED YEARS TO ONSET. Over the 5
years of this study, 5 of the Converted-HD received clin-
ical diagnosis despite having estimated years to onset
scores that would not have predicted this (in 1 case for
30 years); these were labeled unexpected converters.
There was no difference in the ranked estimated years to
clinical diagnosis scores for the unexpected converted and
the nonconverted groups (Mann–Whitney U5 96,
n15 11, n25 5, p5 0.8269, HL5 1.310, 95% CI [–
2.300, 8.600]; Fig 5a). Similarly, the difference in CAPs
score was nonsignificant (U5 84, n15 11, n25 5,
p5 0.3196, HL5 –0.071, 95% CI [–0.213, –0.017];
Fig 5b).
PREDICTION OF CLINICAL DIAGNOSIS FROM IMAG-
ING DATA. A pertinent question was whether the neuro-
imaging measures could provide an alternative prediction of
disease onset. The ranked hypoconnectivity score (U5 90,
n15 11, n25 5, p5 0.7427, HL5 –0.113, 95% CI [–
0.225, 0.027]) or mean CT (U5 96, n15 11, n25 5,
p5 0.8269, HL5 0.019, 95% CI [–0.033, 0.100]) did not
differ between the unexpected converted and the noncon-
verted groups. However, putamen (U5 115, n15 11,
n25 5, p5 0.0133, HL5 1.0798e103, 95% CI [671.700,
1.3962e103]) and caudate volume (U5 113, n15 11,
n25 5, p5 0.027, HL5 723.900, 95% CI [368.500,
988.300]) did significantly differ (Fig 5c).
Rerunning the SVM pipeline using the polymarker
but directly comparing the unexpected converted and the
nonconverted groups classified them with above chance
accuracy (correct5 74%; accuracy, p< 0.03). Further-
more, distance to the classification hyperplane (a measure
of classification strength) for the SVM model comparing
all preHD versus controls using the polymarker feature
set significantly differed between the unexpected con-
verted and the nonconverted preHD individuals (Fig 5d;
U5 83, n15 11, n25 5, p5 0.019, HL5 –59.117,
95% CI [–161.632, –34.691]). Contrasting all converted
individuals versus nonconverted for this measure pro-
vided a robust cross-group difference (U5 86, n15 11,
n25 8, p5 0.002, HL5 –81.818, 95% CI [–170.334, –
50.101]), despite the model having been blind to this
information when trained. Critically, the 8 converted
TABLE 2. Classification Accuracy (%) and Comparison to Randomly Permuted Null Distribution
LOO
External
Rest CT SCV Polymarker SCV
Group
preHD vs controls 67* 65* 72* 74** 72**
preHD-far vs controls 49 63 48 56 48
preHD-near vs controls 89*** 61 73* 84*** 82**
Converted HD vs controls 60 65 88** 81*** 84**
Table reports classification accuracy (F1 scores %) from analyses using a linear support vector machine with leave-one-out (LOO) and external test-
ing. Models were assessed by their F1 scores against a randomly permuted null distribution made up of 1,000 iterations where the group labels
were shuffled. The External column represents models trained on an external data set (TRACK-HD) and tested on the Cambridge cohort.
***>5All permutations; **>599% of permutations; *>595% of permutations. Rest5Between Resting Network coupling. preHD5 all premani-
fest HD individuals (N5 19). Far HD5 individuals who were estimated to be far from receiving a clinical diagnosis (N5 10). Near
HD5 individuals who were estimated to be near to receiving a clinical diagnosis (N5 9). Converted HD5 individuals who became manifest in
the years between data collection and analysis (N5 8).
CT5 cortical thickness; SCV5 subcortical volumes.
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HD individuals were all within the top 10 when preHD par-
ticipants were ranked by classification accuracy, whereas this
was only the case for 3 of them when ranked by estimated
years to onset. Therefore, a simple median split of the HD
group based on the hyperplane distance differentiates indi-
viduals who are within 5 years of developing overt disease
from those who are not with84% to 89% accuracy.
CROSS-COHORT VALIDATION. In a final validation
step, the SVM was trained on SCVs from an external cohort
(TRACK-HD: 118 preHD, 121 controls). The model was
then tested using independent data from the Cambridge
cohort (see Materials and Methods). The preHD-far and
control model performed at chance level (Fig 6A,B). How-
ever, the preHD-all (F15 72%; p< 0.01) and preHD-near
(F15 82%; p< 0.01) versus control models performed with
an above chance accuracy (Fig 6A,B). The HD-converter
model performed above chance when classifying HD-
converters within the Cambridge cohort (F15 84%;
p< 0.01).
Following this, the model trained to differentiate
preHD and controls using the TRACK-HD data set was
applied to the preHD subjects from the Cambridge data
set. This was applied to examine how the HD-converters
and those preHD yet to convert clustered relative to the
SVM hyperplane (Fig 6c). Despite the SVM being na€ıve to
FIGURE 5: Relationship between actual time of diagnosis and estimated years to diagnosis (A), CAG-Age product scaled (B),
caudate volume (C), and SVM classification strength (D). Yellow5expected to phenoconvert within 2 years or less of the analy-
sis date. Red5early diagnosis. Blue5 yet to phenoconvert. SVM5 support vector machine. Yellow5expected to phenoconvert
within 5 years or less of analysis date.
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information regarding symptom onset, 87.5% of converters
were assigned to the same class despite 57% of these receiv-
ing diagnoses before their expected conversion.
Discussion
To our knowledge, this is the first study to combine brain
function and structure to create a polymarker that robustly
identifies whether a patient will receive a real-life clinical
diagnosis within 5 years. A consistent pattern of results
emerged across imaging domains, whereby individuals pre-
dicted to be “near” to diagnosis presented robust differences
relative to those predicted to be “far” from diagnosis and con-
trols, whose performance was similar. The results also dem-
onstrate that combining imaging metrics as a polymarker can
predict whether preHD individuals are within 5 years of clin-
ical diagnosis with greater sensitivity than the Langbehn
model.4 Consequently, a trained classification machine of
this type could be used to assign risk quotients identifying
those near to diagnosis for use in clinical trial recruitment.
A strength of this work is that the SVM was
trained using imaging data from participants with a
definitive date of diagnosis unlike previous neuroimaging
studies, where the relationship was established with a sta-
tistical estimate of proximity to diagnosis that is known
to be inaccurate on an individual basis. The benefit of
this is best illustrated by the relationship between classifi-
cation strength and unexpected diagnosis. The Langbehn
model only accurately identified 3 of the 8 individuals
who did subsequently receive a clinical diagnosis, reveal-
ing a high rate of false negatives. Therefore, given the
increased sensitivity, this model has the potential to be
clinically useful with a greater positive predictive value
than current biomarkers pending a full replication in a
larger cohort.
FIGURE 6: Cambridge data classified with models trained on independent data from the TRACK-HD consortium. (A) Permuted null
distribution F1 scores (pink) relative to the true model (yellow bar, N.B. Bar height and width are arbitrary) for the controls versus
preHD-far (Ai), preHD-all subjects (Aii), and preHD-near (Aiii) models. (B) Confusion matrices for each model. A model trained to clas-
sify preHD versus controls in the TRACK-HD data was used to measure distance to SVM hyperplane when the model was tested on
the Cambridge preHD. (C) Yellow5expected to phenoconvert within 2 years or less of the analysis date. Red5early diagnosis. Blue-
5 yet to be diagnosed. SVM5 support vector machine. Yellow5expected to phenoconvert within 5 years or less of analysis date.
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Although never tested, it is assumed that preHD par-
ticipants transition toward impairment from a normal
baseline. Indeed, we have demonstrated that they have
similar neural profiles to controls and consequently SVM
classification was unsuccessful. This suggests that macro-
scopic structural and functional pathology in the preHD
brain develops from a relatively normal baseline. There-
fore, hypothetically treatment efficacy could be evaluated
against its ability to impede the rate at which an individu-
al’s neuroimaging profile progresses toward the near-HD
classification profile, or by determining whether there is a
degree of normalisation towards the profile of controls.
Although the polymarker was the most successful
classifier of preHD individuals who converted from those
who did not, all the imaging measures independently
yielded a classification accuracy that was significantly bet-
ter than chance. The most sensitive of these independent
measures was subcortical volume, which classified partici-
pants with 88% accuracy. Indeed, the univariate analyses
of the subcortical gray matter identified robust cross-
group differences between the preHD and controls with
the volume of the caudate showing a strong relationship
to the estimated time to clinical diagnosis. Crucially,
when caudate volume was used to retrospectively predict
those patients who were within 5 years of clinical diagno-
sis (Fig 5), this measure was seen to be a robust and
individualized identifier of real-life clinical diagnosis.
These findings accord and extend existing work,9,19–21
providing additional support for the use of caudate vol-
ume as a reliable estimate of disease proximity and mak-
ing it a potentially useful biomarker.
Importantly, the volumetric data were also the only
individual measure capable of distinguishing those partici-
pants who had received an “unexpected diagnosis” from
those who remained disease free. Given the resilience of
these findings, which have been demonstrated consistently
across multiple studies in preHD,22–29 we would suggest
that analyses of subcortical volume becomes a minimum
requirement for any future preclinical disease modifying
trials in HD. Notably, structural volumetric analyses are
likely to be more robust across scanners than resting-state
functional neuroimaging measures; therefore, they are also
more likely to form a tractable basis for a standardized pol-
ymarker that can be used to integrate findings across stud-
ies and sites. This is further supported in the current study
through the independent validation of the structural imag-
ing component of the Cambridge analysis with the multi-
site TRACK-HD baseline data set.13
Nonetheless, the functional connectivity measures
contribute to the accuracy of the polymarker and provide
insight into the likely basis of cognitive abnormalities in
the premanifest and prodromal phases. Specifically, we
observed progressive disruptions to frontostriatal system-
to-system interactions in preHD. Altered resting-state
functional connectivity has previously been shown in
preHD with reduced coupling between the left middle
frontal and precentral gyrus and between the right post-
central gyrus with the medial visual network.30 Our find-
ings identified a more extensive global pattern of
abnormality with greater hypoconnectivity between 10
RSNs in preHD-near than in preHD-far and control
groups. This abnormality showed a strong relationship
with estimated years to clinical diagnosis.
Interestingly, interrogation of the hypoconnectivity
composite revealed extensive abnormal interactions
between the AIFO and other large-scale networks in
preHD. Given the progressive nature of the abnormali-
ties observed, it is likely that degeneration within the
caudate leads to abnormal modulation of AIFO function,
a key node for cognitive control,31 and impacts on more
diffuse network interactions required for executive behav-
iors.32–34 This probably relates to the executive dysfunc-
tion observed in preHD. Consequently, resting-state
fMRI may also be an appropriate biomarker for use in
future therapeutic trials of potential cognitive enhancing
treatments. Further work is needed to confirm the way
in which resting-state network abnormalities develop lon-
gitudinally, and how this impacts on cognitive function,
especially in the light of a recent study that detected no
change over a 3-year period.35
Conversely, the observed hyperconnectivity between
five RSNs did not robustly relate to disease course, and
therefore although this they may relate to functional
reorganisation in preHD, we do not consider them to be
suitable biomarkers.
Finally, our analysis of the cortex detected a preHD
versus control effect of reduced cortical thickness that
was more pronounced in preHD individuals approaching
diagnosis. Consistent with our other analyses, the
preHD-far group did not differ from controls whereas
the preHD-near group showed significantly reduced cor-
tical thickness to both groups.
Multivariate polymarkers of the type developed
here could potentially be used clinically to help preHD
individuals plan their lives more securely, including
employment where gene status can be a major problem
(eg, military, medical profession). Moreover, disease-
modifying therapies are currently being developed with
the intention of delaying the onset of clinical disease.
Using this new neuroimaging polymarker should improve
the selection criteria for such a study by facilitating the
recruitment of participants who really have a high proba-
bility of being within 5 years of diagnosis. This is partic-
ularly relevant in an orphan disease like HD.36
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The main limitation of this study is that our sam-
ple size was restricted by the practical limitations of
recruiting from a low prevalence neurological population.
However, our SVM was robustly validated using a leave-
one-out approach relative to a permutation distribution.
Additionally, we repeated the structural analysis in a
larger, independently acquired data set of premanifest
HD gene carriers, 36% of whom also developed clinical
symptoms of the disease within 5 years, which yielded
consistent results. Moreover, a major strength of our
study was the longitudinal follow-up, which allowed us
to determine classification accuracy in those individuals
not expected to receive a clinical diagnosis within 5 years.
This was an opportunity to evaluate our model against
real-life diagnostic data and to compare its accuracy to
the Langbehn model. In the cross-validation analysis, we
opted to fully replicate the methodology from the origi-
nal data set including deriving a new median split within
the validation cohort. This approach could be criticized
because time-to-onset predictions should not be cohort
dependent. However, we felt that it was important to
respect the a priori analysis plan and, by so doing, to
uphold the integrity of the analysis. In future studies, an
alternative approach could be to use estimated time to
disease onset as a continuous variable in a regression-
rather than classification-based analysis. Finally, clinical
signs of HD develop across a wide range of ages; conse-
quently, the age range for participants in this study was
large (26–68 years old). Despite this, our groups and
subgroups were age matched, and critical cross-group
and correlational effects were significant when age was
carefully factored out.
At present, we know of only one other study that
includes structural and resting MRI measures from
preHD individuals (TRACK-ON) and that could poten-
tially be used to replicate our findings. Unfortunately,
that data are currently unavailable for a replication analy-
sis. Nonetheless, future research should replicate these
results within an independent sample.
In summary, this is the first study to develop a
multimodality neuroimaging polymarker of HD capable
of sensitively identifying individuals who are within 5
years of their real-life clinical diagnosis. We demonstrate
the potential of multivariate statistics to outperform pre-
dictions made by the Langbehn model. Being able to
identify those people who are truly “close” to diagnosis
has both clinical and experimental relevance, providing
both support for gene carriers who wish to work in high-
risk, high-power professions and facilitating the most
efficient and effective recruitment to future disease modi-
fying therapeutic trials.
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